Breaking News
COVID-19

Pitt-UPMC creates possible COVID vaccine

Medical school developed potential inoculation process in seven days

By William Kibler 3 min read

The University of Pittsburgh School of Medicine has developed a potential vaccine for COVID-19 that has worked on mice, and it has applied to regulatory agencies for permission to begin trials on human beings.

While testing in people typically requires at least a year, because of the gravity of the coronavirus pandemic, the school is hoping for an accelerated protocol that could shrink waiting time before the vaccine would be available generally -- if it proves effective, according to a news release and a news conference held Thursday.

Pitt researchers began working on the COVID-19 vaccine on Jan. 21, when the genetic sequence of the virus was published, according to Andrea Gambotto, associate professor of surgery and co-author of a paper on the proposed vaccine published Thursday in EBioMedicine.

Gambotto's co-author, Louis Falo, is a UPMC professor of dermatology and chairman of the dermatology department at Pitt Medicine, where Jonas Salk developed the vaccine that basically eradicated polio 65 years ago.

Multiple doctors were involved in the collaboration at the University of Pittsburgh and UPMC.

The school was able to develop the proposed new COVID vaccine in seven days, based on Gambotto's prior work on vaccines against the SARS virus in 2003 and the MERS virus in 2014, in which he found that a spike protein that is part of all three viruses can induce immunity in test subjects.

After that seven days, the trials with mice began.

In humans, laboratory-constructed pieces of the spike proteins would be delivered under the top layer of skin, where immune reaction is strong, via a fingertip-sized patch like a Band-aid armed with 400 microscopic "needles" of sugar in which the protein is embedded, which would dissolve into the skin, triggering antibodies, according to the doctors.

Flu shots work like this, according to the news release.

One of the advantages of the proposed vaccine and its delivery system is that it is "scalable" -- it could be made in large quantities with fairly simple processes, using a centrifuge and molds, according to the school.

Another is that it could be stored at room temperature -- especially valuable if the vaccine would be used in developing countries, the doctors said.

"For most vaccines, you don't need to address scalability to begin with," Gambotto said in the news release. "But when you try to develop a vaccine quickly against a pandemic, that's the first requirement."

The "surge" of antibodies produced in mice occurred within two weeks and the antibodies generated in mice with the MERS vaccine lasted at least a year, according to the doctors.

The effort on the new vaccine is the first for COVID-19 that has been published after peer review from outside institutions, according to the doctors.

The data from the vaccine effort is posted on the journal's website, representing the "all-on-board" collaboration among researchers trying to find a way to protect people from the coronavirus, Falo said.

How long it would take for the proposed vaccine to be approved "depends on the feedback we get," Falo said. Safety is the "top" concern, he said.

But Pitt will be ready to begin human trials as soon as the agencies approve, Falo said.

While Gambotto previously developed potential vaccines for SARS and MERS, they didn't go to human trials because those weren't funded after the threats evaporated, he said.

Mirror Staff Writer William Kibler is at 949-7038.

Starting at /week.